SPTLC2

Across TCGA pan-cancer cohorts, SPTLC2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SPTLC2 data layer compared with 26 for mass-spec protein and 12 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher SPTLC2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SPTLC2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and HNSC show a favorable association.

LSCC, PDAC, and HNSC are the cancer types where SPTLC2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Quartile	II,III,IV	0.816	0.443	.017	12	view →
PDAC	DFS	Median	All	0.704	0.817	.005	11	view →
HNSC	DFS	Tertile	II,III,IV	0.783	0.543	.019	6	view →
GBM	OS	Median	All	0.401	0.617	.041	3	view →
CCRCC	OS	Tertile	All	0.785	0.927	.046	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SPTLC2–LSCC (DFS)

Open the LSCC breakdown →